AR106307A1 - Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos - Google Patents

Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos

Info

Publication number
AR106307A1
AR106307A1 ARP160103089A ARP160103089A AR106307A1 AR 106307 A1 AR106307 A1 AR 106307A1 AR P160103089 A ARP160103089 A AR P160103089A AR P160103089 A ARP160103089 A AR P160103089A AR 106307 A1 AR106307 A1 AR 106307A1
Authority
AR
Argentina
Prior art keywords
amino acid
substituted
basic
binding portion
antigen binding
Prior art date
Application number
ARP160103089A
Other languages
English (en)
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of AR106307A1 publication Critical patent/AR106307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud proporciona anticuerpos o su porción de unión de antígeno para un antígeno de hidrato de carbono de asociación tumoral. Además se divulgan en esta solicitud composiciones farmacéuticas y métodos para la inhibición de células cancerosas en un sujeto que lo necesita. Las composiciones farmacéuticas comprenden un anticuerpo o una porción de unión de antígeno de este y por lo menos un portador farmacéuticamente aceptable. Reivindicación 1: Un anticuerpo, o una porción de unión de antígeno de este, que se une a un antígeno de hidrato de carbono y comprende una región variable de cadena pesada, donde la región variable de cadena pesada comprende tres regiones de determinación de complementariedad (CDR), CDR1, CDR2 y CDR3, que tienen secuencias de aminoácidos alrededor de 90% hasta alrededor de 100% homólogas a la secuencia de aminoácidos expuesta en SEQ ID Nº 1, 2 y 3, respectivamente; donde el anticuerpo o su porción de unión de antígeno comprende por lo menos una de las siguientes sustituciones de aminoácidos: (a) el residuo de aminoácido 28 en CDR1 está sustituido con un aminoácido básico, un aminoácido neutro que no sea Serina o un aminoácido hidrófobo, (b) el residuo de aminoácido 31 en CDR1 está sustituido con un aminoácido básico, (c) el residuo de aminoácido 57 en CDR2 está sustituido con un aminoácido neutro, uno básico o uno hidrófobo, (d) el residuo de aminoácido 63 en CDR2 está sustituido con un aminoácido neutro, un aminoácido básico o un aminoácido hidrófobo que no sea Prolina, y/o (e) el residuo de aminoácido 105 en CDR3 está sustituido con un aminoácido básico, un aminoácido hidrófobo o un aminoácido neutro.
ARP160103089A 2015-10-07 2016-10-07 Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos AR106307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238680P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
AR106307A1 true AR106307A1 (es) 2018-01-03

Family

ID=58488607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103089A AR106307A1 (es) 2015-10-07 2016-10-07 Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos

Country Status (13)

Country Link
US (2) US10501532B2 (es)
EP (1) EP3359193A4 (es)
JP (1) JP2018536628A (es)
KR (1) KR20180077181A (es)
CN (1) CN108472362B (es)
AR (1) AR106307A1 (es)
AU (1) AU2016335842A1 (es)
BR (1) BR112018006140A2 (es)
CA (1) CA3000531A1 (es)
HK (1) HK1256414A1 (es)
IL (1) IL257956A (es)
TW (1) TWI704159B (es)
WO (1) WO2017062792A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ714555A (en) 2013-09-17 2020-03-27 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
CN108350605A (zh) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11583577B2 (en) 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
US10781265B2 (en) * 2017-05-24 2020-09-22 Development Center For Biotechnology Humanized antibodies against Globo H and uses thereof in cancer treatments
BR112020015568A2 (pt) * 2018-03-13 2020-12-29 F. Hoffmann-La Roche Ag Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
JP2021525756A (ja) * 2018-06-01 2021-09-27 オービーアイ ファーマ，インコーポレイテッド 抗グロボｈ又は抗ｓｓｅａ−４抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
CN116589572B (zh) * 2023-06-28 2023-11-10 湖南诺合新生物科技有限公司 一种抗ha标签的单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
US8551920B2 (en) * 2005-02-01 2013-10-08 Morpho Sys AG Libraries and methods for isolating antibodies
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
TWI583393B (zh) * 2009-06-16 2017-05-21 中央研究院 免疫原性組合物、包含其之疫苗與治療劑及其用途
CA2795799C (en) 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
KR20140064768A (ko) * 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
WO2015015629A1 (ja) 2013-08-02 2015-02-05 株式会社日立製作所 炭化珪素半導体装置および炭化珪素半導体装置の製造方法
CN104693305A (zh) * 2013-12-04 2015-06-10 苏州中赢医疗科技有限公司 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用
CN106456766B (zh) 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
RU2016138744A (ru) 2014-04-10 2018-05-11 Оби Фарма Инк. Антитела, фармацевтические композиции и их применения

Also Published As

Publication number Publication date
HK1256414A1 (zh) 2019-09-20
US10501532B2 (en) 2019-12-10
JP2018536628A (ja) 2018-12-13
KR20180077181A (ko) 2018-07-06
CN108472362B (zh) 2022-03-29
WO2017062792A1 (en) 2017-04-13
TW201718658A (zh) 2017-06-01
CA3000531A1 (en) 2017-04-13
TWI704159B (zh) 2020-09-11
EP3359193A1 (en) 2018-08-15
AU2016335842A1 (en) 2018-04-12
EP3359193A4 (en) 2019-05-08
US20170101462A1 (en) 2017-04-13
CN108472362A (zh) 2018-08-31
IL257956A (en) 2018-06-28
US11236154B2 (en) 2022-02-01
US20200048334A1 (en) 2020-02-13
BR112018006140A2 (pt) 2018-10-23

Similar Documents

Publication Publication Date Title
AR106307A1 (es) Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PE20190737A1 (es) Anticuerpos anti-cd27
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure